Tech Company Financing Transactions
Transition Bio Funding Round
Northpond Ventures, Bristol-Myers Squibb and Lifeforce Ventures invested in a $50 million Series A funding round for Transition Bio. The round was announced on 6/2/2022.
Transaction Overview
Company Name
Announced On
6/2/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Northpond Ventures (Lead Investor) (Shaan Gandhi)
Proceeds Purpose
The capital raised will accelerate the progress made to date with the Company's novel Condensomics platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21 Erie St. C
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Our founders have come together to integrate the latest advancements in the fields of physics, chemistry, biology and machine learning, and to attract top talent from around the world to solve some of today's most fundamental challenges in health and disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Greg Miller
Chief Operating Officer
Martin Kulander
Chief Technical Officer
Tuomas Knowles
Vice President
Joe Grosso
VP - R & D
Shilpi Arora
VP - R & D
Assaf Rotem
Browse more venture capital transactions:
Prev: 6/2/2022: Yummy venture capital transaction
Next: 6/2/2022: Foxen venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs